Cedilla Therapeutics, an oncology biotech founded by a former Editas executive, has snagged an additional $25 million to bring two small-molecule oncology programs into human trials. The financing ...

Bayer is joining Blueprint Medicines, Incyte and Pfizer in the race to develop a selective CDK2 inhibitor, paying Cedilla Therapeutics an undisclosed sum for a preclinical challenger to the more ...

Bayer BAYRY has announced an exclusive license agreement with Cedilla Therapeutics to jointly develop and commercialize the latter’s CyclinE1/CDK2 complex inhibitors for targeted oncogenic treatments.

Third Rock Ventures invested $56.2 million in Series A funding for Cedilla Therapeutics, a biotechnology company concerned with protein stability. With its new funding, Cedilla Therapeutics launched ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a new biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today revealed its two lead conditional inhibitor programs: an ...

The ingredients: 3/4 ounce Cedilla Acai Liqueur, 3/4 ounce lemon juice, 1/2 ounce ginger syrup, Pilsner or wheat beer The process: Shake cedilla, lemon juice, and ginger syrup with ice. Top with beer.

Aspiring to understand and exploit protein stability, Cedilla Therapeutics has launched with $56.2 million in its first formal round of funding from Third Rock Ventures. Cambridge, Mass.-based Cedilla ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the ...